A phase I, randomised, placebo controlled, crossover study to assess the effect of SRT2104 on exercise tolerance and muscle metabolism in subjects with type 2 diabetes.
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2016
At a glance
- Drugs SRT 2104 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SRTAiD
- 07 Jun 2013 Additional lead trial centre added as reported by United Kingdom Clinical Research Network record.
- 26 Jul 2011 Status changed from not yet recruiting to suspended as reported by United Kingdom Clinical Research Network.
- 30 Oct 2009 New trial record